


Advanta V12 FEVAR and BEVAR Long-Term Data



Eric Verhoeven MD, PhD, A. Katsargyris, MD
Department of Vascular and Endovascular Surgery
Paracelsus Medical University, Nuremberg, Germany

Disclosures

- Cook: Consultant, Speaker, Research Grants
- Maquet Getinge: Consultant, Speaker
- Bentley: Consultant, Speaker

Lay-Out

- Literature (Bridging stents in F/BEVAR)
- Advanta V12
 - Nuremberg Experience
- Imaging Study Advanta V12 Groningen/Nürnberg
 - Paper submitted

Cleveland Clinic Experience

Durability of branches in branched and fenestrated endografts

Tara M. Mastracci, MD, Roy K. Greenberg, MD, Matthew J. Eagleton, MD, and Adrian V. Hernandez, PhD,
Cleveland, Ohio

(J Vasc Surg 2013;57:926-33.)

- 650 pts with FEVAR/BEVAR
 - Mean F/U: 3 ± 2.3 years (range: 1-9 years)
- Reintervention for
 - CA: 0.6%, SMA: 4%, Renal arteries: 5.5%
- Branch related mortality: n=3 (0.46%)
 - All three due to mesenteric ischemia

Cleveland Clinic Experience

Durability of branches in branched and fenestrated endografts

Tara M. Mastracci, MD, Roy K. Greenberg, MD, Matthew J. Eagleton, MD, and Adrian V. Hernandez, PhD,
Cleveland, Ohio

(J Vasc Surg 2013;57:926-33.)

Branches in FEVAR/BEVAR are Durable and Rarely
the Cause of Patient Death

Fenestrations or Branches for Renal Arteries in TAAAB grafting?

Mid-term Outcomes of Renal Branches Versus Renal Fenestrations for Thoraco-abdominal Aneurysm Repair[☆]

T. Martin-Gonzalez^a, T. Mastracci^b, T. Carrell^c, J. Constantinou^b, N. Dias^d, A. Katsargyris^e, B. Modarai^c, T. Resch^d, E. Verhoeven^e, S. Haulon^{a,*}


Eur J Vasc Endovasc Surg (2016) 52, 141–148

- 449 pts (235 BEVAR, 214 FEVAR)

Fenestrations or Branches for Renal Arteries in TAAAB grafting?

Fenestrations significantly better patency rates!

Branches significantly higher instability (occlusion/reintervention)



Advanta V12 (Getinge)


- Covered Balloon-Expandable Stent
- Indication: restoring and improving the patency of iliac and renal arteries
- Off-Label Use in F/B-EVAR

Updated Nuremberg Experience (2010-2020)

- TAAA: N=426
 - Advanta V12: N=1202 (76.3%)
- Pararenal: N=582
 - Advanta V12: N= 1258 (92.3%)
- IBD: N= 130 (154 IBDs)
 - Advanta V12: N=123 (76.6%)

Total Advanta V12: 2583/3104 (83.2%)


Advanta V12 Patency (N=2453)*



97.6 ± 0.4% at 1 year
94.2 ± 0.7% at 5 years

*IBD Excluded

Advanta V12 Patency (N=2453)



- Fenestrations

- 98.6 ± 0.5% at 1 year
- 95.1 ± 1.2% at 5 years

- Branches

- 96.5 ± 0.7% at 1 year
- 90.8 ± 1.4% at 5 years

P<0.001*

Discussion

- Advanta V12 used as Bridging stent-graft
 - High Durability
 - Fenestrations better than branches?
 - Excellent patency rates!
 - Excellent handling and flaring!
- Imaging Study Groningen/Nürnberg
 - initiated by Prof JP de Vries



Patient #2

- 61 YO Male Pt
- 3xFEVAR
 - RRA: Advanta 6x22
 - LRA: Advanta 7x22
 - SMA: Advanta 8x38 + 8x40 SE





SMA

1 Month



4 Years




RRA & LRA


1 Month




4 Years




1 Month




4 Years



1 Month



4 Years



Conclusion

- Advanta V12 BE Covered Stent works well in F/BEVAR
 - In Fenestrations 95%
 - In Branches 90%
- Interest in bridging stentgrafts increases
- Competition is open!
 - BeGraft and BeGraft PLUS (on-label studies pending)
 - Viabahn VBX